Search

Your search keyword '"Rodriguez, Moses"' showing total 243 results

Search Constraints

Start Over You searched for: Author "Rodriguez, Moses" Remove constraint Author: "Rodriguez, Moses" Database MEDLINE Remove constraint Database: MEDLINE
243 results on '"Rodriguez, Moses"'

Search Results

1. Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis.

2. Distinct plasma lipids predict axonal injury and multiple sclerosis activity.

3. Early Adversity and Socioeconomic Factors in Pediatric Multiple Sclerosis: A Case-Control Study.

4. Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.

5. An Injury-like Signature of the Extracellular Glioma Metabolome.

6. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease.

7. Clinical and magnetic resonance imaging outcomes in pediatric-onset MS patients on fingolimod and ocrelizumab.

8. Association of nutritional intake with clinical and imaging activity in pediatric multiple sclerosis.

9. Gene-environment interactions and risk of pediatric-onset multiple sclerosis associated with time spent outdoors.

10. Assessing Needs and Perceptions of Research Participation in Pediatric-Onset Multiple Sclerosis: A Multistakeholder Survey.

11. Methodological and analytical considerations for intra-operative microdialysis.

12. Characteristics and predictors of disease course in children initially presenting with ADEM.

13. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.

14. Mechanisms of metabolic stress induced cell death of human oligodendrocytes: relevance for progressive multiple sclerosis.

15. Gene-environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures.

16. Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas.

17. Patients with ACPA-positive and ACPA-negative rheumatoid arthritis show different serological autoantibody repertoires and autoantibody associations with disease activity.

18. Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.

19. Rare and low-frequency coding genetic variants contribute to pediatric-onset multiple sclerosis.

20. Silent findings: Examination of asymptomatic demyelination in a pediatric US cohort.

21. Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.

22. MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls.

23. Axonal response of mitochondria to demyelination and complex IV activity within demyelinated axons in experimental models of multiple sclerosis.

24. A new look at cognitive functioning in pediatric MS.

25. Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition.

26. A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse.

27. Association Between Time Spent Outdoors and Risk of Multiple Sclerosis.

28. Gut microbiome is associated with multiple sclerosis activity in children.

29. Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis.

30. Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials.

31. Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.

32. Remyelination-Promoting DNA Aptamer Conjugate Myaptavin-3064 Binds to Adult Oligodendrocytes In Vitro.

33. Pediatric Multiple Sclerosis Severity Score in a large US cohort.

34. Improved relapse recovery in paediatric compared to adult multiple sclerosis.

35. Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis.

36. Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis.

37. Vitamin D genes influence MS relapses in children.

38. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.

39. Antibody characterization using immunosignatures.

40. Relapse recovery: The forgotten variable in multiple sclerosis clinical trials.

41. Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells.

42. Age is a critical determinant in recovery from multiple sclerosis relapses.

43. Optimization of a 40-mer Antimyelin DNA Aptamer Identifies a 20-mer with Enhanced Properties for Potential Multiple Sclerosis Therapy.

44. Glial cells as therapeutic targets in progressive multiple sclerosis.

45. miRNA contributions to pediatric-onset multiple sclerosis inferred from GWAS.

46. Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis.

47. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry.

48. Acute vision loss in multiple sclerosis: Optic neuritis or central serous chorioretinopathy?

49. IgM Natural Autoantibodies in Physiology and the Treatment of Disease.

50. Genetic risk factors for pediatric-onset multiple sclerosis.

Catalog

Books, media, physical & digital resources